ARS Pharmaceuticals Announces FDA Approval of Needle-Free Epinephrine Spray 'neffy'

ARS Pharmaceuticals has achieved a significant milestone with the FDA approval of neffy^®, a groundbreaking epinephrine nasal spray designed as a needle-free alternative for treating severe allergic reactions, including anaphylaxis. This revolutionary product marks the first new delivery method for epinephrine in over three decades, offering a much-needed option for both adults and children weighing at least 30 kilograms who suffer from Type I allergic reactions.

FDA Greenlights neffy^® for Emergency Allergic Responses

The approval of neffy^® by the US Food and Drug Administration ushers in a new era for emergency treatment of allergic reactions. As the only needle-free epinephrine solution available, neffy^® provides a non-invasive and user-friendly alternative to traditional epinephrine auto-injectors. This development is especially significant given the vast number of individuals living with severe allergies and the critical importance of rapid response during an anaphylactic episode.

ARS Pharmaceuticals Prepared to Support neffy^® Launch

Well-financed and ready for the commercial rollout of neffy^® in the United States, ARS Pharmaceuticals, trading under the ticker SPRY, has secured the necessary capital to support the product launch. With a strong financial foundation, the company anticipates it will have sufficient operational runway for at least three years, ensuring that neffy^® reaches those who need this life-saving medication.

Optimism for a Needle-Free Future in Allergy Treatment

After decades without significant innovation in the method of delivery for epinephrine, neffy^® stands as a pioneering treatment for those at risk of severe allergic reactions. This approval not only represents a significant advancement for patient care but also showcases ARS Pharmaceuticals' commitment to innovation and providing new solutions for unmet medical needs.

neffy, FDA, needle-free, epinephrine, allergic, anaphylaxis, innovation, SPRY